# REQ-0000020479 (nivolumab): what clinicians are saying

> 34 statements from 14 sources (2 videos, 11 posts, 1 registry record), 13 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026.

## Report

- Trial: Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study
- NCT ID: NCT03993249
- Registry: https://clinicaltrials.gov/study/NCT03993249
- Sponsor: Hellenic GenitoUrinary Cancer Group
- Phase: Phase 2
- Status: Unknown
- Drugs tested: nivolumab
- Indication: muscle-invasive bladder cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-22 UTC
- Last checked: 2026-11-22 UTC
- Release hash: 339e9e25be2557cde8b9698e238b4e447f4597b4d7684a0565c2281e708e3160

## Counts

- Commentary sources screened: 17
- Sources cited by verified statements: 14
- Verified statements: 34
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 13
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 14
- Speakers cited: 14
- Cited speakers with a verified identity: 13
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 7
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 7
- By role and specialty (the abstract's specialty counts):
  - 6 physician, Radiation oncology
  - 1 physician, Medical oncology
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited read REQ-0000020479 as supporting phase III testing because of reported survival gains, rather than justifying routine use. A radiation oncologist reports that the local-control benefit was not statistically significant; another questions cisplatin as the sole chemotherapy agent. The statements leave the severity and management burden of added immune adverse events unclear. The sources reviewed for this edition place the phase II results at ESTRO2025.

## Question clinicians left open

What do clinicians say a randomized phase III trial must establish about overall survival before they would add nivolumab to chemoradiotherapy for muscle-invasive bladder cancer in patients not undergoing cystectomy?

From finding F1 (10 statements from 6 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Phase II efficacy: what most speakers highlight; some seek phase III testing
  - 10 statements from 6 speakers in 6 sources, 1 of them a podcast or video.
  - 5 of the 6 named speakers in this finding hold this view; 3 of the 6 hold its caveat, “some seek phase III testing”.
  - 2 of the report's 7 cited clinicians.
- F2. Survival: what speakers note; one awaits primary local-control data
  - 6 statements from 5 speakers in 5 sources, 1 of them a podcast or video.
  - 5 of the 5 named speakers in this finding hold this view; 1 of them holds its caveat, “one awaits primary local-control data”.
  - 2 of the report's 7 cited clinicians.
- F3. Control arm: what speakers say
  - 5 statements from 2 speakers in 3 sources.
  - 2 of the report's 7 cited clinicians.
- F4. Safety signals: what speakers highlight; a clinician notes more immune toxicity
  - 6 statements from 4 speakers in 5 sources.
  - 4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician notes more immune toxicity”.
  - 1 of the report's 7 cited clinicians.
- F5. Chemotherapy compliance: most clinicians await S1806; one notes agents differ
  - 4 statements from 3 speakers in 2 sources.
  - 2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one notes agents differ”.
  - 2 of the report's 7 cited clinicians.
- F6. MIBC label: what speakers say
  - 4 statements from 3 speakers in 3 sources, 1 of them a podcast or video.
  - 2 of the report's 7 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 10 | 8 | 6 | 6 | 2 |
| F2 | 6 | 5 | 5 | 5 | 3 |
| F3 | 5 | 3 | 3 | 2 | 2 |
| F4 | 6 | 6 | 5 | 4 | 2 |
| F5 | 4 | 4 | 2 | 3 | 3 |
| F6 | 4 | 5 | 3 | 3 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 9 | 1 | 0 | 0 | 0 | 10 | 0 | 5 posts and articles, 1 podcast or video |
| F2 | 4 | 1 | 0 | 0 | 1 | 6 | 0 | 4 posts and articles, 1 podcast or video |
| F3 | 2 | 1 | 0 | 1 | 1 | 5 | 0 | 3 posts and articles |
| F4 | 4 | 0 | 0 | 0 | 2 | 6 | 0 | 5 posts and articles |
| F5 | 3 | 1 | 0 | 0 | 0 | 4 | 0 | 2 posts and articles |
| F6 | 1 | 2 | 0 | 0 | 1 | 5 | 0 | 2 posts and articles, 1 podcast or video |

### Trial dimensions

- Primary endpoint: Locoregional control rate: F2 (2 shared claims)
- Secondary endpoint: Incidence Rate of treatment-related adverse event (safety and tolerability): F2 (2 shared claims), F4 (5 shared claims)
- Secondary endpoint: Bladder cancer failure-free (BCFF) rates: F2 (3 shared claims), F4 (2 shared claims)
- Secondary endpoint: Median overall survival (OS): F1 (4 shared claims), F2 (5 shared claims), F4 (3 shared claims), F5 (1 shared claims)
- Secondary endpoint: Assessment of the effect of the combined treatment on the quality of life: no finding draws on it directly
- Population and setting: F1 (1 shared claims), F6 (4 shared claims)
- The comparison: F1 (3 shared claims), F3 (5 shared claims), F5 (1 shared claims)
- Safety and tolerability: F2 (2 shared claims), F4 (6 shared claims), F5 (1 shared claims)
- Design and conduct: F1 (5 shared claims), F2 (1 shared claims), F3 (1 shared claims), F5 (3 shared claims), F6 (1 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 13 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 14 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 7 of the 14 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Locoregional control rate | discussed | 2 | 2 |
| Secondary endpoint: Incidence Rate of treatment-related adverse event (safety and tolerability) | discussed | 5 | 5 |
| Secondary endpoint: Bladder cancer failure-free (BCFF) rates | discussed | 3 | 3 |
| Secondary endpoint: Median overall survival (OS) | discussed | 10 | 10 |
| Secondary endpoint: Assessment of the effect of the combined treatment on the quality of life | no commentary found | 0 | 0 |
| Population and setting | discussed | 5 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 8 | 5 |
| Safety and tolerability | discussed | 6 | 5 |
| Design and conduct | discussed | 11 | 5 |
| Phase III validation and clinical adoption | discussed | 14 | 10 |
| Chemotherapy compliance and interpretation of forthcoming studies | discussed | 6 | 3 |
| Endpoint terminology and proposed distant-relapse explanation | discussed | 8 | 7 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 7 statements · 21%** | | | |
| YouTube | 7 | 2 | 2 |
| **Posts · 26 statements · 76%** | | | |
| X threads | 26 | 11 | 15 |
| **Primary sources · 1 statement · 3%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2020-12-09 to 2026-11-09
- Cited window: 2024-09-16 to 2026-11-09
- Retrieved: 2026-11-22

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study
- Registry: NCT03993249 (https://clinicaltrials.gov/study/NCT03993249)
- Study IDs: REQ-0000020479
- Sponsor: Hellenic GenitoUrinary Cancer Group
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Unknown
- Enrollment: 78 (estimated)
- Start: 2019-05-28 (actual)
- Primary completion: 2022-08 (estimated)
- Primary endpoint: Locoregional control rate (2 years)
- Intervention: Nivolumab (biological)
- Intervention: chemoradiotherapy (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 8 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 121 sources about other trials or topics are not included.
- No full protocol was listed in the reviewed registry material, and no results publication was available for the exact trial. The registry evidence describes planned methods, not observed outcomes.
- Several relevant statements describe the study’s regimen, population or clinical question without naming NCT03993249. They inform interpretation of the decision but should not automatically be treated as independently identified reports of this trial’s results.
- Interview publication dates and X post dates do not establish presentation dates or a change of opinion. Expectations about endpoint maturity and forthcoming studies are preserved at the time they were expressed.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The reviewed statements do not resolve detailed endpoint equivalence, exact treatment-delivery differences, immune-event burden or quality-of-life effects.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-22 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-22 UTC. No changes.

## Offer

- Size: Focused · 34 verified statements · 13 from 7 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (13 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/req-0000020479-nct03993249
- Agents: POST https://www.erudio.com/api/orders with {"report": "req-0000020479-nct03993249", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=req-0000020479-nct03993249

## Cite

Erudio Health. REQ-0000020479 (NCT03993249): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/req-0000020479-nct03993249

## Questions

### How much does the REQ-0000020479 report cost?

One edition costs $750 (Focused · 34 verified statements · 13 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the REQ-0000020479 report cover?

34 statements from 14 sources (2 videos, 11 posts, 1 registry record), 13 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the REQ-0000020479 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "req-0000020479-nct03993249" }) previews it and create_order({ "report": "req-0000020479-nct03993249", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the REQ-0000020479 report?

Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/req-0000020479-nct03993249.json
- Markdown: https://www.erudio.com/reports/req-0000020479-nct03993249.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/req-0000020479-nct03993249/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "req-0000020479-nct03993249"}`
